Suppr超能文献

靶向神经营养因子:治疗肌肉骨骼疼痛的新方法。

Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.

机构信息

Division of Rheumatology, Rush University Medical Center, 1611 W Harrison Street, Suite 510, Chicago, IL 60612, United States of America.

Division of Rheumatology, Rush University Medical Center, 1611 W Harrison Street, Suite 510, Chicago, IL 60612, United States of America.

出版信息

Pharmacol Ther. 2020 Jul;211:107553. doi: 10.1016/j.pharmthera.2020.107553. Epub 2020 Apr 18.

Abstract

Chronic pain represents a substantial unmet medical need globally. In recent years, the quest for a new generation of novel, safe, mechanism-based analgesic treatments has focused on neurotrophic factors, a large group of secreted proteins that control the growth and survival of different populations of neurons, but that postnatally are involved in the genesis and maintenance of pain, with biological activity in both the periphery and the central nervous system. In this narrative review, we discuss the two families of neurotrophic proteins that have been extensively studied for their role in pain: first, the neurotrophins, nerve growth factor (NGF) and brain-derived growth factor (BDNF), and secondly, the GDNF family of ligands (GFLs). We provide an overview of the pain pathway, and the pain-producing effects of these different proteins. We summarize accumulating preclinical and clinical findings with a focus on musculoskeletal pain, and on osteoarthritis in particular, because the musculoskeletal system is the most prevalent source of chronic pain and of disability, and clinical testing of these novel agents - often biologics- is most advanced in this area.

摘要

慢性疼痛是全球范围内未满足的重大医学需求。近年来,人们致力于寻找新一代新型、安全、基于机制的镇痛治疗方法,将重点放在神经营养因子上。神经营养因子是一大类分泌蛋白,可控制不同神经元群体的生长和存活,但在出生后参与疼痛的发生和维持,在外周和中枢神经系统中均具有生物活性。在本综述中,我们讨论了两种已广泛研究的神经营养蛋白家族,它们在疼痛中起作用:首先是神经营养因子,包括神经生长因子(NGF)和脑源性神经营养因子(BDNF),其次是 GDNF 配体(GFLs)家族。我们概述了疼痛途径以及这些不同蛋白质产生疼痛的作用。我们总结了积累的临床前和临床发现,重点关注肌肉骨骼疼痛,特别是骨关节炎,因为肌肉骨骼系统是慢性疼痛和残疾最常见的来源,并且这些新型药物(通常是生物制剂)在该领域的临床测试最为先进。

相似文献

1
Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.
Pharmacol Ther. 2020 Jul;211:107553. doi: 10.1016/j.pharmthera.2020.107553. Epub 2020 Apr 18.
2
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
Drugs. 2017 Sep;77(13):1377-1387. doi: 10.1007/s40265-017-0781-6.
3
Managing musculoskeletal pain in an elderly woman.
J Pain Palliat Care Pharmacother. 2013 Aug;27(3):286-7; discussion 287-8. doi: 10.3109/15360288.2013.817500. Epub 2013 Aug 2.
4
Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review.
BioDrugs. 2021 Nov;35(6):611-641. doi: 10.1007/s40259-021-00504-8. Epub 2021 Nov 22.
7
Pharmacologic Therapies in Musculoskeletal Conditions.
Med Clin North Am. 2016 Jul;100(4):869-90. doi: 10.1016/j.mcna.2016.03.015. Epub 2016 Apr 20.
8
Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?
Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78. doi: 10.1038/nrrheum.2016.224.
9
The evolution of nerve growth factor inhibition in clinical medicine.
Nat Rev Rheumatol. 2021 Jan;17(1):34-46. doi: 10.1038/s41584-020-00528-4. Epub 2020 Nov 20.
10
Translational musculoskeletal pain research.
Best Pract Res Clin Rheumatol. 2011 Apr;25(2):209-26. doi: 10.1016/j.berh.2010.01.013.

引用本文的文献

1
Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain.
Nat Rev Rheumatol. 2025 Aug 12. doi: 10.1038/s41584-025-01280-3.
4
Osteoarthritis.
Nat Rev Dis Primers. 2025 Feb 13;11(1):10. doi: 10.1038/s41572-025-00594-6.
7
The role of obesity and adipose tissue dysfunction in osteoarthritis pain.
Nat Rev Rheumatol. 2024 Sep;20(9):565-584. doi: 10.1038/s41584-024-01143-3. Epub 2024 Aug 7.
8
Axonopathy Underlying Amyotrophic Lateral Sclerosis: Unraveling Complex Pathways and Therapeutic Insights.
Neurosci Bull. 2024 Nov;40(11):1789-1810. doi: 10.1007/s12264-024-01267-2. Epub 2024 Aug 4.
9
Inflammation in the Peripheral Nervous System after Injury.
Biomedicines. 2024 Jun 5;12(6):1256. doi: 10.3390/biomedicines12061256.
10
Assessment of Neuropathic Pain in Erosive Hand Osteoarthritis.
J Clin Med. 2024 May 31;13(11):3244. doi: 10.3390/jcm13113244.

本文引用的文献

1
Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis.
Osteoarthritis Cartilage. 2020 May;28(5):581-592. doi: 10.1016/j.joca.2020.01.008. Epub 2020 Jan 23.
3
No pain, no gain? The effects of pain-promoting neuropeptides and neurotrophins on fracture healing.
Bone. 2020 Feb;131:115109. doi: 10.1016/j.bone.2019.115109. Epub 2019 Nov 9.
5
Fracture repair requires TrkA signaling by skeletal sensory nerves.
J Clin Invest. 2019 Dec 2;129(12):5137-5150. doi: 10.1172/JCI128428.
6
Peripheral brain-derived neurotrophic factor contributes to chronic osteoarthritis joint pain.
Pain. 2020 Jan;161(1):61-73. doi: 10.1097/j.pain.0000000000001694.
8
Nerve growth factor-mediated photoablation of nociceptors reduces pain behavior in mice.
Pain. 2019 Oct;160(10):2305-2315. doi: 10.1097/j.pain.0000000000001620.
9
Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial.
Osteoarthritis Cartilage. 2019 Nov;27(11):1590-1598. doi: 10.1016/j.joca.2019.05.029. Epub 2019 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验